IFNL4 and Cirrhosis: In the BOSON study, patients were randomised to receive sofosbuvir with ribavirin for 16 or 24 weeks or for 12 weeks with accompanying Peg‐IFN.10 To understand the impact of IFNL4 genotype on attaining SVR, we estimated the effect size (odds ratio; OR) of IFNL4 CC versus non‐CC on achieving SVR stratified by the cirrhosis status in the two IFN‐free treatment arms.